We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

64 hedge funds and large institutions have $189M invested in Protagonist Therapeutics in 2019 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more capital invested

Capital invested by funds: $93.2M → $189M (+$96.1M)

7.22% more ownership

Funds ownership: 57.29% → 64.51% (+7.2%)

4% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 23

7% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 14

3% less funds holding

Funds holding: 66 → 64 (-2)

Holders
64
Holders Change
-2
Holders Change %
-3.03%
% of All Funds
1.38%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
13
Increased
24
Reduced
23
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GTC
Ghost Tree Capital
New York
+$6.18M
2
BBA
Baker Bros. Advisors
New York
+$3.57M
3
VMI
VHCP Management III
New York
+$3.41M
4
ACP
Acuta Capital Partners
California
+$2.98M
5
Citadel Advisors
Citadel Advisors
Florida
+$2.9M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$6.43M
2
BI
BVF Inc
California
-$4.56M
3
FCM
Farallon Capital Management
California
-$3.62M
4
American Century Companies
American Century Companies
Missouri
-$762K
5
SIM
Spark Investment Management
New York
-$746K
Name Holding Trade Value Shares
Change 		Change in
Stake
JT
51
Jump Trading
Illinois
$159K +$111K +12,624 New
T. Rowe Price Associates
52
T. Rowe Price Associates
Maryland
$150K -$81.2K -9,200 -44%
SAM
53
Sectoral Asset Management
Quebec, Canada
$143K – – –
Bank of Montreal
54
Bank of Montreal
Ontario, Canada
$139K +$91.8K +10,405 +1,676%
AG
55
Algert Global
California
$132K -$31.4K -3,554 -25%
SIM
56
Spark Investment Management
New York
$126K -$746K -84,500 -89%
Morgan Stanley
57
Morgan Stanley
New York
$57K +$477 +54 +1%
UBS Group
58
UBS Group
Switzerland
$21K -$1.92K -218 -12%
KPW
59
Kore Private Wealth
New York
$13K – – –
MAM
60
Meeder Asset Management
Ohio
$8K -$2.41K -273 -30%
Federated Hermes
61
Federated Hermes
Pennsylvania
$2K +$1.54K +174 New
FGAM
62
Financial Gravity Asset Management
Texas
$1K +$485 +55 New
TC
63
Truvestments Capital
Florida
$1K +$1.05K +119 New
BNP Paribas Financial Markets
64
BNP Paribas Financial Markets
France
$50 -$4.09K -463 -99%
GPP
65
Great Point Partners
Connecticut
– -$6.43M -955,618 Closed
American Century Companies
66
American Century Companies
Missouri
– -$762K -113,155 Closed
MIM
67
Monashee Investment Management
Massachusetts
– -$289K -42,945 Closed
Arrowstreet Capital
68
Arrowstreet Capital
Massachusetts
– -$192K -28,602 Closed
BFM
69
Boothbay Fund Management
New York
– -$134K -19,917 Closed
TI
70
Trexquant Investment
Connecticut
– -$123K -18,317 Closed
TRCT
71
Tower Research Capital (TRC)
New York
– -$48K -7,128 Closed
Macquarie Group
72
Macquarie Group
Australia
– -$15K -2,282 Closed
TAM
73
Tiverton Asset Management
Delaware
– -$15K -2,193 Closed
Royal Bank of Canada
74
Royal Bank of Canada
Ontario, Canada
– -$3K -500 Closed
EP
75
Elkfork Partners
Oregon
– -$3K -442 Closed
1 2
3
4

PTGX Hedge Fund Activity: Q1 2019 in Review

64 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2019, worth a combined $189M — up 103% from $93.2M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of PTGX and 13 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 24 added.

The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $6.18M. The largest seller was Great Point Partners, exiting entirely with an estimated $6.43M sold.

  • 64 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2019, down from 66 in Q4 2018.
  • Funds reported $189M of Protagonist Therapeutics stock for Q1 2019, up 103% quarter-over-quarter.
  • 13 funds opened new Protagonist Therapeutics positions in Q1 2019 and 14 closed out, a net change of -1 holder.
  • The largest Protagonist Therapeutics buyer in Q1 2019 was Ghost Tree Capital, an estimated $6.18M added.
  • The largest Protagonist Therapeutics seller in Q1 2019 was Great Point Partners, an estimated $6.43M sold.

Based on aggregated 13F filings for Q1 2019.